{"id":"W4400240704","doi":"10.4103/iju.iju_62_24","title":"Combination therapy for advanced urothelial cancer: LEAP-011 trial","year":2024,"lang":"en","type":"article","venue":"Indian Journal of Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Pembrolizumab; Medicine; Lenvatinib; Internal medicine; Hazard ratio; Placebo; Adverse effect; Oncology; Randomized controlled trial; Confidence interval; Cancer; Sorafenib; Immunotherapy; Pathology; Hepatocellular carcinoma","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002050873,0.0001236087,0.0003297619,0.0002266473,0.00004636061,0.0000200827,0.00008808422,0.0001139427,0.0002533393],"category_scores_gemma":[0.00004593535,0.00009183915,0.0002210906,0.0001135095,0.00005537045,0.0001043593,0.000005312764,0.0002410271,0.0000114755],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008849271,"about_ca_system_score_gemma":0.0006274871,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000124833,"about_ca_topic_score_gemma":0.000008005502,"domain_scores_codex":[0.9990807,0.00005047635,0.0003547356,0.0001438716,0.0001645545,0.0002056933],"domain_scores_gemma":[0.9994001,0.0001178975,0.0001322614,0.00009227552,0.0001446205,0.0001128338],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.2624706,0.001011431,0.002325207,0.0001532073,0.001767764,0.001446697,0.002963253,0.00005030895,0.01025095,0.001241336,0.008181241,0.708138],"study_design_scores_gemma":[0.3824889,0.07340913,0.004315138,0.0002341123,0.0008974544,0.00272092,0.0001414262,0.0001238719,0.01086869,0.01116029,0.5132544,0.0003856596],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9662541,0.01218511,0.0008029691,0.01349231,0.005534117,0.001122428,0.00005706289,0.0000342157,0.0005176531],"genre_scores_gemma":[0.9948279,0.001472453,0.0001903125,0.001286107,0.00164567,0.00006944078,0.000006374281,0.00003244112,0.0004693587],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7077523,"threshold_uncertainty_score":0.3745092,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02451463644948239,"score_gpt":0.3369613821673754,"score_spread":0.312446745717893,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}